Clinical trial NCT03889834: Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 Ml) in Healthy Volunteers.
Official title: Modification of Biological Parameters After Autologous Blood Transfusion of a Small Volume of Packed Red Blood Cells (200 Ml) in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: The Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy Volunteers
Keywords: autologous transfusion
doping
blood markers
detection
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Laboratoire antidopage français (LADF)
name: World Anti-Doping Agency
name: GR-Ex executive comitee
name: Institut National de la Santé Et de la Recherche Médicale, France
name: Etablissement Français du Sang
First posted: 2019-03-26
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate if differences between samples of subjects obtained before autologous blood transfusion or samples of non-transfused subjects and samples of subjects after autologous blood transfusion can be identified. Analyses performed will focus on the morphological and biochemical parameters of red blood cells and associated microparticles. The final goal would be to find markers of autologous blood transfusion, that could be used to identify such doping practice.

Detailed description: Methodology and study design:

Pr Olivier Hermine, coordinator of the laboratory of Excellence GR-EX regrouping EFS (Etablissement Français du Sang) and INSERM (Institut National de la Santé et de la Recherche Médicale) partners, and leader of the Centre d'Investigation Clinique (CIC) Necker (Hospital Necker, Paris, France) will assure the promotion of the clinical study for Paris Hospital consortium AP-HP (assistance Publique-Hôpitaux de Paris).

To reproduce two potential scenarios of autologous transfusion by an athlete, 1 bag of blood packed red blood cells (after leuko deprivation and centrifugation) will be either stored at 4°C or frozen at -80°C after addition of 40% w/v glycerol. Reinfusion will be performed 31 days later.

A clinical randomized double-blinded two-phase study will be conducted. Volunteers will be separated in 3 groups:

* Group 1: Volunteers with regular sports activities without Autologous Blood Transfusion (ABT)T (n=10)
* Group 2: Volunteers with regular sports activities receiving a 200ml ABT with refrigerated blood (n=10)
* Group 3: Volunteers with regular sports activities receiving a 200ml ABT with frozen blood (n=10)

To ensure volunteers safety, collection, preparation and pretransfusion blood testing will be performed by EFS (Versailles, France). ABT as well as collection of samples will be performed at the CIC Necker (Paris, France). Blood samples will be collected before blood removal, the day of the ABT just before reinfusion and after 3 hours, 8 hours, 24 hours and 48 hours post-ABT. To perform all the experiments 25ml blood (4x 5 ml BD Vacutainer EDTA tubes) will be taken at each time point:

1 will be dispatched to the French anti-doping laboratory (LADF) for haematological analysis (Orsay, France), 2 to the EFS (Créteil, France) for RBC and MPs morphological characterization and quantification (using antigen markers, band 3 on the surface of MPs), 2 to INTS for MPs isolation, characterization (band 3 on the surface of MPs and RBC) and for proteomic analysis and Western-Blot.

Eligibility criteria: Inclusion Criteria:

* Male between 18 and 35 years old
* Without health problem nor disease requiring regular medical treatment
* Free from any intercurrent acute pathology over 7 days
* Healthy volunteers who have regularly sport activity, able to have blood sample and is out-of-competition during the research
* Subject who did not practice a competition (or exhaustive training ) 3 days before the blood sample and the autotransfusion
* Affiliated to a social security regimen

Exclusion Criteria:

* Subject with contraindication for drawing blood
* Subject with medical pathology contraindicating sport practice
* Subject under treatments or drugs in the list of products prohibited for sports practice and competitions, in particular erythropoeitins and erythropoiesis-stimulating agents (updated list of World Anti-Doping Agency https://www.wada-ama.org/fr/liste-des-restrictions).
* Subject with physical or mental disability or restriction of liberty that would prevent autotransfusion
* Subject without a social security regimen
* Subject under guardianship or curatorship
* Subject participating in any Interventional study
* Positive HIV and/or hepatitis serology
* Discovery of a hematological disease

Primary outcomes:
measure: Change in hematological parameters
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Change in hematological parameters
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Change in hematological parameters
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Change in hematological parameters
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Change in hematological parameters
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Variation in Red blood cells morphology
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Change in expression of cell surface proteins in red blood cells transfusion
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
measure: Change in microparticles detected in plasma
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
Secondary outcomes:
measure: Change in phthalate in urine
timeFrame: Baseline (Day 1), until 2 days after autotransfusion
Other outcomes:
Locations:
city: Le Chesnay-Rocquencourt
country: France
facility: EFS de Versailles, centre de soins
Study officials:
affiliation: Assistance Publique-Hôpitaux Paris
name: Olivier HERMINE, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: